ArvindChaudhryMD

Oncology • Spokane, WA

Physician

Join to view full profile

Dr. Chaudhry is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chaudhry's full profile

Already have an account?

Office
6001 North Mayfair
Spokane, WA 99208
Phone+1 509-462-2273

Fax+1 509-462-2275

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1993 - 1996
Christian Medical College LudhianaClass of 1989

Certifications & Licensure

ID State Medical License 2019 - 2026
WA State Medical License 1999 - 2026
IA State Medical License 1995 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 Sep 24
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
ACTIVE_NOT_RECRUITING
PHASE3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
Completed
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jan 01
Terminated
Join now to see all

Publications & Presentations

PubMed

1 citations
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, Seth D Rosen, Christoper J Hoimes
Journal for Immunotherapy of Cancer. 2024-11-20
1 citations
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter
Haematologica. 2024-07-01
1 citations
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Andrea Necchi, Rodryg Ramlau, Alejandro Falcón González, Arvind Chaudhry, Tilman Todenhöfer
JNCI Cancer Spectrum. 2024-04-30

Press Mentions

American Oncology Network Physicians Research Presented at 64th ASH Annual Meeting & ExpositionDecember 14th, 2022
Vial Announces Dr. Arvind Chaudhry of Summit Cancer Centers as a New Member of Vial’s Oncology CRO Advisory BoardJuly 27th, 2022
American Oncology Network Physicians Research Presented at ASCO22June 13th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member